The issue of pharmaceutical kickbacks

The measure tweaks the mechanism, which nevertheless remains a risk factor for investment and innovation. The Bruno Leoni Institute’s comparative study on the UK, Spain, Portugal and France

20 NOV 26
Translated by AI
The issue of pharmaceutical kickbacks
 In its 2027 Budget Bill, the government proposes two changes to the pharmaceutical payback scheme—the mechanism under which, since 2012, companies in the sector have been required to cover half of the amount by which expenditure on medicines purchased directly by the National Health Service (NHS) exceeds the statutory spending cap. Article 71, on the one hand, proposes raising that ceiling by 0.2 percentage points from 2028, bringing it up to 9 per cent of NHS funding. On the other hand, however, it provides for a reduction in the payback, up to a total of 160 million euros per year, for pharmaceutical companies that increase their eligible investments in Italy year on year.
According to a study by the Bruno Leoni Institute, entitled “Oltre il payback” and authored by Paolo Belardinelli, these are “useful measures” which, however, leave the structural issue unresolved: as long as the cap remains lower than actual expenditure, half of the difference continues to fall on businesses as an amount they do not know in advance, and this has negative consequences for investment planning. The levy payable by businesses in 2013 was initially estimated by AIFA at 364 million euros and has risen to around 2.4 billion for 2025.
The study’s first criticism concerns precisely the nature of the mechanism, described as ‘an additional, variable and unpredictable levy’. Exceeding the limit depends, in fact, on factors beyond the control of individual companies, such as doctors’ prescriptions, the introduction of new treatments and the level of the cap. Companies, on the other hand, are required to supply medicines in accordance with the reimbursement conditions set by AIFA, but only become aware of the amount to be paid once the financial year has ended (and it is precisely the provision that requires companies to bear 50 per cent of the cost of exceeding the cap – which, according to the study, may make it too easy to set caps below actual requirements – that the Constitutional Court must now rule on, to which the Lazio Regional Administrative Court has referred the matter).
The study also compares the Italian system with those of other countries such as the UK, France, Spain and Portugal, showing that measures to curb pharmaceutical expenditure exist elsewhere too, but with elements that are weak or absent in Italy (such as explicit limits on the overall expenditure and multi-year agreements). France applies similar rates, ranging from 50 to 70 per cent of expenditure exceeding the annual target; however, for 2025, for example, the law stipulated that the levy on each company could not exceed 10 per cent of their turnover. In the United Kingdom, the levy is governed by an agreement between the government and the pharmaceutical industry: in 2026, the rate payable is 14.5 per cent of turnover for the most recently marketed medicines, whilst those containing a new active ingredient remain temporarily exempt. In Spain, companies pay a contribution equivalent to 1.5 or 2 per cent of sales of prescription-only medicines funded by the health service, with a discount of between 5 and 25 per cent on the levy based on an assessment of their research and production activities.
However, the US ‘Most Favoured Nation’ policy – whereby the White House uses the price actually paid in other countries, net of rebates, as a benchmark for setting drug prices – has introduced a further complication. Indeed, an Italian price made lower by the retrospective application of payback affects the benchmark used by the United States – for certain medicines – to reference the net prices of a basket of countries that also includes Italy. If payback lowers the Italian price used as a benchmark, a company might delay the launch of a medicine in Italy to avoid a price reduction on the US market.
The objective set out in the paper remains to overcome the payback period in the medium term, given that immediate abolition is not “politically or fiscally feasible”. The study therefore proposes an agreement of at least four years between the state and the industry that sets in advance the National Health Service’s spending ceiling, the rates and the payment schedule; a cap on the overall burden and on that of individual companies; finally, an exemption from the payback scheme for new medicines during the first two years following their inclusion on the reimbursement list, followed by a further two years at a reduced rate, as well as a reduction in the levy for companies investing in Italy. Of these proposals, however, the budget bill only includes the last one, which, if approved, will come into effect as early as 2026.